This commercial progress comes in the midst of a challenging period for the Company, as communicated earlier. The new sales contribute positively to short-term liquidity and signal continued customer demand for Eevia's premium organic bioactive ingredients. Orders confirmed this week include:

• EUR 18,000 for FENO-SAMBUCUS® SKUs (Elderberry extracts)
• EUR 10,000 for FENOPROLIC® Organic SKUs (Pine bark extracts)
• EUR 9,700 for FENO-MYRTILLUS® Organic SKUs (Bilberry extracts)
• EUR 6,100 for FENO-CERASUS® Organic SKUs (Tart cherry extracts)
• EUR 6,000 for other high-strength polyphenol extracts

All products are available from inventory, allowing for immediate delivery and avoiding delays related to raw material procurement. These inventory-based sales directly support cash flow improvements in the current quarter.

"While Eevia is facing financial challenges, these orders highlight the strength of our product portfolio and the trust we continue to build in global markets. Every step like this supports our ongoing efforts to stabilize operations and pursue a sustainable turnaround." - Stein Ulve, CEO of Eevia. "The continued demand for Eevia's high-quality, organic nutraceutical ingredients underscores the Company's market relevance and aligns with its recently announced plan to restructure operations and relocate production to regions more supportive of sustainable health innovation."

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com                      

Telephone: +358 400 22 5967                         

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.

Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.